Immenstadt Im Allgau

Accidental hypothermia, especially severe cases with core body temperatures below 28C, can be life-threatening and often results from accidents like snow sports, near drowning, or urban cold exposure. Researchers aim to better understand the causes, treatment methods, and complications of accidental hypothermia through the International Hypothermia Registry. This observational study collects worldwide data to improve knowledge on patient outcomes and treatment approaches. The study gathers detailed information on accidental hypothermia cases, including prehospital and hospital treatments, rewarming techniques, and patient outcomes. Both prospective and retrospective cases are included without limits on the year of occurrence. The registry collects data through a comprehensive questionnaire covering demographics, clinical status, treatments, and outcomes. Participants provide information during and after treatment, with data recorded in a secure database over an average follow-up of one year. Researchers analyze these data to identify survival predictors, optimal rewarming methods, and ways to prevent complications after rewarming. The registry aims to develop evidence-based guidelines for diagnosing and treating accidental hypothermia to improve patient care worldwide.

Researchers are evaluating the effectiveness and safety of Adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced non-small cell lung cancer NSCLC who have the KRAS G12C mutation. The study includes a Phase 2 portion focusing on patients with various PD-L1 scores and a Phase 3 portion comparing Adagrasib plus pembrolizumab versus pembrolizumab alone in patients with high PD-L1 levels. This research aims to improve first-line treatment options for advanced NSCLC. The Phase 2 study has three groups two cohorts with low PD-L1 scores receiving either Adagrasib alone or combined with pembrolizumab, and one cohort with higher PD-L1 scores receiving the combination. In Phase 3, patients are randomly assigned to receive either Adagrasib with pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given by intravenous infusion every three weeks. Participants will undergo regular assessments over 22 months for Phase 2 and 36 months for Phase 3, including evaluations of tumor response, safety, quality of life, and drug levels in the blood. Brain imaging is also used to check for metastases. Researchers will monitor progression-free survival, duration of response, and side effects to understand the treatments impact and tolerability throughout the study period.